Especially with the COVID-19 pandemic impacting studies, the company says, putting patients at the center of studies and trial tech must be top priority.
A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
An expert speaking at the April 6 Clinical Development Innovations event will discuss an app that matches patients with clinical research opportunities.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
Two experts from CRO Phastar talk about how trial professionals face new, ever-changing challenges regarding collecting and disseminating patient data.
The company’s Patient Advisory Council brings together a range of people and perspectives to help ensure increased diversity, inclusivity and engagement.
The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.
Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.
The results of a recent Phase III study show caregivers can gauge by individual age, functional status to adapt treatment approaches to specific patients.
The companies are joining on a hybrid clinical trial to test a potential COVID-19 treatment, featuring an ambitious remote patient monitoring strategy.
A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
The Verisense Pulse+ can measure heart rate, oxygen saturation, emotional responses, and activity and sleep levels of at-home clinical trial participants.
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
The partnership reportedly will center on optimizing integration for EHR data and remote-source data review to help accelerate clinical research results.
An executive from the rare disease technology solutions company discusses how forcing connections with patients can boost research into such conditions.
An executive from the clinical trial technology provider will share how direct data capture can save time, avoid errors and improve the patient experience.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
A senior clinical research associate from the CRO discusses how the pandemic has touched her workday, and how she is dealing with the myriad challenges.
The technology is designed to streamline and simplify integration, data collection and analysis, and digital biomarker discovery with wearable sensors.
The on-pack technology enables consumers, retailers and others to harness mobile devices in order to verify the authenticity of pharmaceutical products.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
A study by two trial technology firms reportedly indicates that decentralized trials are outperforming on-site in recruitment, retention and other aspects.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
According to a company leader, electronic clinical outcome assessment solutions should take ease of use for patients, sponsors and others into account.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
